Six years is long enough to take a pure-play biosimilar company from private ambition to listings on three separate exchanges, and that is precisely the tenure Tanya Zharov is closing out as she steps down as Alvotech’s General Counsel. The timing matters: Alvotech now carries five approved biosimilars across major markets — including its adalimumab, ustekinumab, and denosumab entries — plus nine pipeline candidates, a commercial partnership network spanning the U.S., Europe, Japan, and China, and the full weight of maintaining regulatory standing in each of those jurisdictions simultaneously. The legal architecture holding that together is not a background function; it is load-bearing infrastructure.
What makes this departure structurally interesting is where Zharov lands. She is not exiting the orbit — she is moving to board-level legal responsibility for Wessman’s holding companies, Aztiq and Flóki. Aztiq is the vehicle through which Wessman controls Alvotech itself. That means the person who built Alvotech’s legal foundation is now positioned upstream of the company, at the ownership layer. That is not a clean break; it is a reorganization of influence. Her successor, Lisa Graver, steps into the GC seat at a moment when Alvotech’s commercial execution — not its formation — is the dominant legal challenge: biosimilar patent litigation, interchangeability designations, payer contracting disputes, and evolving pricing regulation across multiple markets all simultaneously demand senior legal judgment.
The relocation dynamic adds another layer. Zharov’s departure appears connected, at least in part, to a broader executive pattern of the company concentrating its leadership physically in Reykjavik. Several of her colleagues have made that move; she has not. For a company competing on the argument that a single integrated Icelandic manufacturing hub is a strategic advantage over distributed Big Pharma biosimilar operations, keeping executive decision-making in Iceland is brand-consistent — but it does constrain the talent pool, particularly for a GC role that requires deep fluency in U.S. and European regulatory law.
Graver’s first real test will be the U.S. market, where Alvotech’s Humira biosimilar competes in a crowded interchangeable field and where any slip in FDA correspondence or patent defense compounds immediately into commercial damage. Watch her first public regulatory filing under her own name — that document will signal whether Alvotech’s legal continuity is real or cosmetic.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
